--- title: 'Industry Daily Summary: What Happened on November 9, 2026' headline: argenx agrees to buy Unnatural Products for up to $1.15 billion description: The deal adds peptide discovery capabilities to argenx’s antibody research. Siemens Healthineers plans a diagnostics separation, and Labcorp has completed its Millennium Health acquisition. url: https://thebench.bio/news/industry/2026-11-09 topic: industry date: '2026-11-09' covers: - '2026-11-09' date_published: '2026-11-09T12:03:19Z' date_modified: '2026-11-10T00:02:58Z' tags: - Industry - Funding sources: 6 publisher: TheBench.Bio --- # Industry Daily Summary: What Happened on November 9, 2026 **argenx agrees to buy Unnatural Products for up to $1.15 billion** The deal adds peptide discovery capabilities to argenx’s antibody research. Siemens Healthineers plans a diagnostics separation, and Labcorp has completed its Millennium Health acquisition. ## Today in brief argenx will pay $550 million upfront for Unnatural Products, with up to $595 million more tied to development and regulatory milestones. [1] [2] The acquisition gives argenx full ownership of its peptide-discovery partner, whose platform the company says could support oral or long-acting immune medicines. [2] [3] Siemens Healthineers plans to separate its in vitro diagnostics business as Olyrian Diagnostics, with completion expected by mid-2028. [4] Labcorp completed its $375 million acquisition of Millennium Health, including a $245 million upfront payment. [5] ## argenx takes full ownership of peptide discovery partner argenx agreed to buy the remaining shares of Unnatural Products, in which it had invested and held a minority stake. [1] [2] The deal includes $550 million in cash at closing and up to $595 million in development and regulatory milestone payments, for a maximum stated value of about $1.15 billion. [1] [2] The companies began a multi-target research collaboration in July 2025, giving argenx options to develop and commercialize oral macrocyclic peptides against targets it selects. [1] [2] Macrocyclic peptides are ring-shaped molecules. Unnatural Products uses machine learning and experiments to design them. [2] [3] argenx said the platform complements its antibody engineering and could support oral or long-acting medicines for immune-mediated diseases. [2] [6] The company expects Unnatural Products’ team and leadership to remain in Santa Cruz, planned as argenx’s peptide-discovery hub. [2] [3] The acquisition is slated to close by the end of 2026, pending customary closing conditions. [2] [3] ## Also worth knowing - Siemens Healthineers plans to separate its in vitro diagnostics business as Olyrian Diagnostics, which will remain within Siemens Healthineers until the separation is expected to finish by mid-2028. [4] - Labcorp completed its $375 million purchase of Millennium Health, including $245 million upfront. The deal extends Labcorp’s drug-testing business geographically. [5] ## The day in numbers - **$550 million**: argenx’s upfront payment for Unnatural Products. [1] [2] - **Up to $595 million**: Additional payments tied to development and regulatory milestones. [1] [2] - **Mid-2028**: Expected timeframe for Siemens Healthineers’ diagnostics separation. [4] - **$375 million**: Value of Labcorp’s completed acquisition of Millennium Health. [5] ## Also published - [Digital Health’s GLP-1 Strategy: “You Didn’t Come for the Drug. You Came for Health”](), MedCity News - [The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers](), BioPharm International - [Argenx to buy peptide platform in potentially billion-dollar deal](), BioPharma Dive - [Healthcare wants patients at the centre. So, why are they still outside the room?](), pharmaphorum - [ASHG Notes: Myra Liquid Handler](), Omics! Omics! - [argenx Acquires Unnatural Products Inc. to Expand Immunology Capabilities](), Pharmaceutical Executive - [Biotech in Switzerland: 10 companies to watch in 2027 ](), Labiotech - [When Drug Pricing Collides With Politics](), Pharmaceutical Commerce - [argenx agrees Unnatural takeover deal worth up to $1.15bn](), pharmaphorum - [Moderna to relocate its UK HQ to London's Tribeca](), pharmaphorum - [Find opportunity in a shifting life sciences market](), MedTech Dive - [Making the ‘impossible’ executable in life sciences construction](), BioPharma Dive - [State incentives for commercial-stage life sciences companies](), BioPharma Dive - [Notable TechBio startups and companies operating in India 🇮🇳 (I)](), MetaphysicalCells ## Sources 1. [argenx buys macrocycle partner Unnatural Products for up to $1.15 billion](), European Biotechnology, 2026-11-09 2. [argenx Agrees to Buy Unnatural Products in Up to $1.15 Billion Deal](), BioPharm International, 2026-11-09 3. [Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition](), MedCity News, 2026-11-09 4. [Siemens Healthineers’ Spin-off Olyrian Diagnostics Targets Lab Modernization](), Inside Precision Medicine, 2026-11-09 5. [Labcorp completes $375M Millennium Health takeover](), MedTech Dive, 2026-11-09 6. [Pharmaceutical Executive Daily: argenx Acquires Unnatural Products Inc.](), Pharmaceutical Executive, 2026-11-09 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: [4]: [5]: [6]: